MedBulletinsAura Celeste
Emergency & ICU

Monthly emergency and critical care medicine bulletin — November 11, 2026

🎧 Listen to this issueAudio newscast · 5:47 min

Period covered: October 12 to November 11, 2026. The AHA meeting (Chicago, November 6–9) produced a large trial of cardiac arrest response systems, and the rest of the month brought a pragmatic vasopressin trial in septic shock, an international ventilation trial in pediatric ARDS, a Class I ventilator recall, and two population studies. This issue brings together six items.

Resuscitation and cardiac arrest

1. RACE-CARS: training communities and dispatchers did not improve out-of-hospital cardiac arrest survival

[Clinical trial] [Congress] [United States]
A five-year county-randomized trial (July 2021 to June 2026) in 60 North Carolina counties (about 8.5 million residents): 31 received free community CPR and AED training, training for 911 telecommunicators and EMS personnel, and 405 defibrillators; 29 continued usual care. It included 22,459 adults with out-of-hospital cardiac arrest (11,615 vs 10,844). Survival to discharge with favorable neurological function was about 9% vs 9.4% (no significant difference); bystander CPR was 44.8% vs 42.3% (not significant), and defibrillation before EMS arrival was 13.5% vs 15.3%. In an exploratory analysis of the final year of the trial, the odds of bystander CPR were 33% higher in intervention counties. Presented as a late-breaking abstract at the AHA Scientific Sessions on November 8, 2026, and simultaneously published in NEJM; funded by the NIH and the NHLBI.
Why it matters: a large negative trial that calls for humility: mass training did not by itself produce more survivors, and the final-year rise in bystander CPR comes from an exploratory analysis; the result does not invalidate training, but it argues for measuring real-world execution (telephone recognition, time to first shock) instead of counting people trained.

Sources

Sepsis, shock and intensive care

2. VASSPR: earlier vasopressin did not reduce mortality in septic shock

[Clinical trial] [United States]
A pragmatic, open-label, cluster-randomized trial with monthly crossover in 13 hospitals in Utah and Idaho, enrolling 3,959 adults with septic shock (February 2024 to July 2025). It compared starting vasopressin at a low threshold (0.1 µg/kg/min norepinephrine equivalent) vs a high threshold (0.4 µg/kg/min). Twenty-eight-day mortality was 31.8% vs 33.0% (adjusted OR 0.98; 95% CI 0.87 to 1.06); no differences at 90 days, in-hospital, or in kidney replacement therapy–free days. Cardiogenic shock was somewhat more frequent with the low threshold (7.4% vs 6.3%; exploratory outcome). Published in JAMA on October 14, 2026; funded by the Intermountain Foundation and NCATS.
Why it matters: strict adherence was limited (57.5% vs 73.2%), the shock definition was pragmatic rather than Sepsis-3, and about 23% of patients never reached 0.07 µg/kg/min norepinephrine equivalent, which dilutes the separation between strategies, so the interval does not exclude a small benefit; in practice, there is no reason to routinely start vasopressin earlier.

Sources

3. PROSpect: neither early prone positioning nor high-frequency oscillation improves pediatric ARDS

[Clinical trial] [Multinational: 18 countries]
An international, 2×2 factorial, response-adaptive phase 3 trial in 75 pediatric intensive care units in 18 countries, with 424 children with moderate-to-severe pediatric acute respiratory distress syndrome (May 2019 to January 2026). It compared early prone vs supine positioning and high-frequency oscillatory ventilation vs conventional ventilation. Neither strategy increased ventilator-free days through day 28 (medians of 17.9 vs 17.4 days for prone vs supine, and 17.3 vs 18.0 for HFOV vs conventional ventilation); overall 28-day mortality was 10% (41 patients), with no differences between groups. Prone positioning was associated with more airway obstruction (6% vs 2%) and stage 2 or higher pressure injuries (6% vs 1%), and HFOV with more hemodynamic instability (13% vs 9%). Published in The Lancet on October 31, 2026; funded by the NIH (NHLBI).
Why it matters: although pediatric, it is central to ICUs caring for critically ill children: the authors do not recommend routine use of either strategy as first-line care. The trial was stopped early for futility and slow enrollment after 424 of 600 planned patients, which reduces the precision of the estimates; it also did not evaluate prone positioning or HFOV as rescue therapy, so it allows no conclusion about that use.

Sources

Time-critical emergencies and toxicology

4. US overdoses: EMS data show no relative rise in naloxone and suggest fewer overdoses

[Publication] [United States]
A research letter using nearly 186 million EMS activations (May 2020 to December 2025), of which 2.5 million were nonfatal overdoses (40.5% opioid-related). From May 2023 onward, activations for nonfatal opioid overdoses averaged about 6,000 below expected (roughly 33% lower) and EMS naloxone administrations fell about 21%; there was no signal of increased bystander naloxone use before EMS arrival. The EMS data show no increase in naloxone use relative to the number of overdoses and suggest that fewer overdoses contribute to the decline in deaths; the authors did not directly examine the causes of that decline. Published in JAMA on October 21, 2026.
Why it matters: this observational analysis of EMS records cannot capture naloxone rescues where 911 was never called, so it does not rule out other causes or diminish naloxone's value.

Sources

5. Korea: nearly one million ED visits for falls in adults 65+ and more admissions outside metropolitan areas

[Publication] [South Korea]
A nationwide time-series analysis and projection study using Korea's National Emergency Department Information System (NEDIS, 2016 to 2023): 943,692 fall-related visits by adults aged 65 or older. Authors from the National Medical Center in Seoul, with collaborators from other institutions; published online in BMJ Public Health on October 27, 2026; funded by the Korea Disease Control and Prevention Agency and the National Research Foundation of Korea. Admission rates were 34.9% in metropolitan areas vs 42.8% in non-metropolitan areas; by population density, 34.3% in high-density, 44.0% in middle-density and 46.7% in low-density districts. Vertebral column injuries were 13.5% in metropolitan vs 17.4% in non-metropolitan areas. Projections estimate that by 2040 these visits will be 2.0 to 4.1 times the 2023 figure, depending on the scenario.
Why it matters: a descriptive registry study with no intervention, but useful for planning: the authors expect population aging to raise these visits markedly, and clinical severity was greater in non-metropolitan and low-density areas; the findings come from the Korean health system.

Sources

Cross-cutting

6. Class I recall of the Ventec (React Health) VCSN+Pro ventilator and an alert for the whole VOCSN family

[Regulatory FDA] [United States]
On October 20, 2026, the FDA posted a Class I recall (the most serious type) of the VCSN+Pro ventilator (model PRT-01184-000; recall Z-0128-2027, all serial numbers, 4,368 units) from Ventec Life Systems, doing business as React Health. The internal flow transducer cable connector may disconnect from the board, causing a system reboot and interruption of ventilation. The firm initiated the recall on September 17, 2026. That specific recall covers only the VCSN+Pro model; earlier, on September 23, 2026, an FDA Early Alert had warned that the issue affects all VOCSN device configurations with serial numbers 112786 and higher (including VOCSN, VOCSN+Pro, VC+Pro, VCSN+Pro, V+Pro, VC and V*Home). According to that alert, the probability of a reboot during ventilation is remote and, as of August 12, 2026, no serious injuries or deaths had been reported.
Why it matters: services using any of these devices, including imported or donated units, should check model and serial numbers with their supplier and keep alternative ventilation ready at the bedside of every ventilator-dependent patient, as the manufacturer recommends.

Sources

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.